Novavax to Present at the 15th Annual Needham Healthcare Conference
Get Alerts NVAX Hot Sheet
Join SI Premium – FREE
GAITHERSBURG, Md., April 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq: NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C. Erck, President and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference.
Conference details are as follows:
Date: Wednesday, April 13, 2016Time: 8:40 a.m. U.S. Eastern TimeLocation: Westin Grand Central hotel, New York CityLive webcast: http://wsw.com/webcast/needham76/nvax
The webcast and a replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271Source: Novavax, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Washington Trust Collects 2.5 Tons of Peanut Butter
- Publication Annual Report 2023 and convocation of the Ordinary General Meeting on May 29 2024
- GRAND CANYON UNIVERSITY CELEBRATES ANOTHER GRADUATING CLASS OF NEARLY 30,000
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Davenport, Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!